KEAP1/NRF2 Program
Myocardial Infarction
Pre-clinicalActive
Key Facts
About Grove Biopharma
Grove Biopharma is a private, pre-clinical-stage biotech developing a breakthrough platform for intracellular drug delivery. Its core technology, Bionic Biologics™, uses precision polymerization to create synthetic, cell-permeable polymers that can engage challenging intracellular protein-protein interaction targets. The company has demonstrated proof-of-concept across several high-value targets, including MYC and KRAS, and is backed by a $30 million Series A financing to advance its pipeline in oncology, neurodegenerative diseases, and rare disorders.
View full company profileTherapeutic Areas
Other Myocardial Infarction Drugs
| Drug | Company | Phase |
|---|---|---|
| VANADIS® BMOV | CFM Pharma | Phase 1 |
| QuickProfile Cardiac Markers | LumiQuick Diagnostics | Commercial |
| Lead Peptide Program | ResoTher Pharma | Phase 2a |
| Myocardial Infarction Cardiac Patch | Matricelf | Preclinical |